摘要
目的 探讨百令胶囊预防PD-1抑制剂肺癌患者免疫相关性肺炎(CIP)的临床效果。方法 选取2021年5月至2022年5月九江市第一人民医院肿瘤内科住院且使用免疫检查点抑制剂(ICIs)的晚期肺癌患者60例,按随机数字表法分为对照组和试验组,每组各30例。对照组给予PD-1抑制剂治疗,试验组在对照组基础上加用口服百令胶囊。比较两组临床疗效,生活质量[生存质量卡氏(KPS)评分],不良反应,1年后生存情况,CIP发生情况。结果 治疗4个周期后,试验组疾病控制率(DCR)高于对照组,差异有统计学意义(P<0.05)。两组治疗前KPS评分比较,差异无统计学意义(P>0.05);两组治疗4个周期后KPS评分均高于治疗前,且试验组KPS评分高于对照组,差异有统计学意义(P<0.05)。试验组各项不良反应发生率均低于对照组,差异有统计学意义(P<0.05);随访1年,试验组生存率为90.00%(27/30),高于对照组的63.33%(19/30),差异有统计学意义(P<0.05)。治疗期间试验组CIP发生率低于对照组,差异有统计学意义(P<0.05)。结论 使用PD-1抑制剂肺癌患者应用百令胶囊治疗能够有效改善患者病情,提升患者生活质量,降低CIP发生风险,且不良反应较少,安全可靠,并可提升患者生存率,值得推广应用。
Objective To investigate the clinical effect of bailing capsules on prevention of checkpoint inhibitor pneumonitis(CIP)in lung cancer patients with PD-1 inhibitor.Methods A total of 60 patients with advanced lung cancer who were admitted to the Department of Oncology of Jiujiang First People's Hospital from May 2021 to May 2022 and were treated with immune checkpoint inhibitors(ICIs)were divided into control group and experimental group according to random number table method,with 30 cases in each group.The control group was treated with PD-1 inhibitor,and the experimental group was treated with oral bailing capsules on the basis of the control group.The clinical efficacy,quality of life(KPS scores),adverse reactions,survival after 1 year and CIP occurrence were compared between the two groups.Results After 4 cycles of treatment,the disease control rate(DCR)of the experimental group was higher than that of the control group,the difference was statistically significant(P<0.05).There was no significant difference in KPS scores between the two groups before treatment(P>0.05).After 4 cycles of treatment,the KPS scores of both groups was higher than that before treatment,and the KPS scores of the experimental group was higher than that of the control group,with statistical significance(P<0.05).The incidence of adverse reactions in the experimental group was lower than that in the control group,the difference was statistically significant(P<0.05).After 1-year follow-up,the survival rate of the experimental group was 90.00%(27/30),which was higher than that of the control group 63.33%(19/30),the difference was statistically significant(P<0.05).The incidence of CIP in the experimental group was lower than that in the control group,and the difference was statistically significant(P<0.05).Conclusion The treatment of lung cancer patients with PD-1 inhibitor with bailing capsules can effectively improve the condition of patients,improve the quality of life of patients,reduce the risk of CIP,have fewer adverse reactions,are safe and reliable,and can improve the survival rate of patients,worthy of promotion and application.
作者
王志
石鑫
刘月
刘秋连
WANG Zhi;SHI Xin;LIU Yue;LIU Qiulian(Jiujiang First People's Hospital,Jiujiang Jiangxi 332000,China)
出处
《药品评价》
CAS
2024年第6期720-723,共4页
Drug Evaluation
基金
江西省中医药管理局科技计划项目(2022A149)。
关键词
肺癌
卡瑞利珠单抗
百令胶囊
免疫相关性肺炎
生活质量评分
生存率
Lung cancer
Carrilizumab
Bailing capsules
Checkpoint inhibitor pneumonitis
Quality of life scores
Survival rate
